- Home
- QIPT vs KOD Comparison
QIPT vs KOD Comparison
Compare QIPT & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QIPT
- KOD
- Stock Information
- Founded
- QIPT 1993
- KOD 2009
- Country
- QIPT United States
- KOD United States
- Employees
- QIPT N/A
- KOD N/A
- Industry
- QIPT
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QIPT
- KOD Health Care
- Exchange
- QIPT Nasdaq
- KOD Nasdaq
- Market Cap
- QIPT 92.2M
- KOD 188.9M
- IPO Year
- QIPT N/A
- KOD 2018
- Fundamental
- Price
- QIPT $1.78
- KOD $3.95
- Analyst Decision
- QIPT Buy
- KOD Hold
- Analyst Count
- QIPT 2
- KOD 3
- Target Price
- QIPT $2.85
- KOD $9.00
- AVG Volume (30 Days)
- QIPT 614.3K
- KOD 293.9K
- Earning Date
- QIPT 08-13-2025
- KOD 08-13-2025
- Dividend Yield
- QIPT N/A
- KOD N/A
- EPS Growth
- QIPT N/A
- KOD N/A
- EPS
- QIPT N/A
- KOD N/A
- Revenue
- QIPT $240,848,000.00
- KOD N/A
- Revenue This Year
- QIPT $3.35
- KOD N/A
- Revenue Next Year
- QIPT $5.39
- KOD N/A
- P/E Ratio
- QIPT N/A
- KOD N/A
- Revenue Growth
- QIPT N/A
- KOD N/A
- 52 Week Low
- QIPT $1.35
- KOD $1.92
- 52 Week High
- QIPT $4.07
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- QIPT 44.77
- KOD 56.10
- Support Level
- QIPT $1.75
- KOD $3.60
- Resistance Level
- QIPT $2.18
- KOD $3.94
- Average True Range (ATR)
- QIPT 0.09
- KOD 0.25
- MACD
- QIPT -0.02
- KOD 0.02
- Stochastic Oscillator
- QIPT 17.54
- KOD 77.61
About QIPT Quipt Home Medical Corp.
Quipt Home Medical Corp provides in-home monitoring equipment, supplies, and services to patients. The Company operates in one business segment, which is the sale and rental of medical equipment and related devices. The company's services consist of Daily and Ambulatory Aides, Power Mobility, INR Self-Testing, Respiratory Equipment Rental, Home ventilation, Oxygen Therapy, and Sleep Apnea and PAP Treatment.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.